Everolimus Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (2.5 mg Tablets, 5 mg Tablets, 7.5 mg Tablets, and 10 mg Tablets); End Use (Oncology, Organ transplant, Gastrointestinal, and Others); Distribution Channel (Hospitals, Pharmacy, and Others), and Geography

Report Code: TIPRE00022705 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming

Covid
Assesing the covid-19 impact?
Get the Latest COVID-19 Analysis on this market
Request Now
Happy to join you in your fight against the COVID-19 economic pandemic!
MARKET OVERVIEW

Everolimus is called as afinator or zortress, afinator is a cancer medicine that hinders the growth of cancer cells and reduces development of cancerous cell in the body. It is used for treatment of certain types of cancer such as kidney, breast, brain tumor, and others. Another brand of everolimus is known as zortress, which is used as an immunosuppressant to aid in organs transplant and avoid rejection of transplanted organ by body.

MARKET SCOPE

The "Global Everolimus Market Analysis to 2028" is a specialized and in-depth study of the pharmaceuticals industry with a special focus on the global market trend analysis. The report aims to provide an overview of the everolimus market with detailed market segmentation by type, end use, distribution channel and geography. The report provides key statistics on the market status of the leading everolimus market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION

  •  Based on type, the global everolimus market is segmented into 2.5 mg tablets, 5 mg tablets, 7.5 mg tablets, 10 mg tablets.
  •  On the basis of end use, the market is segmented into oncology, organ transplant, gastrointestinal, others.
  •  On the basis of distribution channel, the market s segmented into hospitals, pharmacy, others

MARKET DYNAMICS
Drivers

  •   Rise in the incidences of cancer and tumor diseases.
  •   Increase in organ transplant surgeries.

Restraints

  •   The insufficient manufacturers and high cost are the major restraining factor for this market.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The everolimus market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.

The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the marketduring the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the everolimus market in these regions.

IMPACT OF COVID-19 ON EVEROLIMUS MARKET
COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the everolimus market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from everolimus market are anticipated to lucrative growth opportunities in the future with the rising demand for everolimus in the global market.

The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the everolimus market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.

  •  Novartis
  •  Biscon
  •  Transopharm
  •  Tecoland Corporation
  •  Gonane Pharma
  •  Biocon Limited
  •  Brawn Laboratories Ltd.
  •  Bright Gene Bio-Medical Technology
  •  Cipla
  •  Concord Biotech

The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Everolimus Market - By Type
1.3.2 Everolimus Market - By End Use
1.3.3 Everolimus Market - By Distribution Channel
1.3.4 Everolimus Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. EVEROLIMUS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. EVEROLIMUS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. EVEROLIMUS MARKET - GLOBAL MARKET ANALYSIS
6.1. EVEROLIMUS - GLOBAL MARKET OVERVIEW
6.2. EVEROLIMUS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING
7. EVEROLIMUS MARKET - REVENUE AND FORECASTS TO 2028 - TYPE
7.1. OVERVIEW
7.2. TYPE MARKET FORECASTS AND ANALYSIS
7.3. 2.5 MG TABLETS
7.3.1. Overview
7.3.2. 2.5 mg Tablets Market Forecast and Analysis
7.4. 5 MG TABLETS
7.4.1. Overview
7.4.2. 5 mg Tablets Market Forecast and Analysis
7.5. 7.5 MG TABLETS
7.5.1. Overview
7.5.2. 7.5 mg Tablets Market Forecast and Analysis
7.6. 10 MG TABLETS
7.6.1. Overview
7.6.2. 10 mg Tablets Market Forecast and Analysis
8. EVEROLIMUS MARKET - REVENUE AND FORECASTS TO 2028 - END USE
8.1. OVERVIEW
8.2. END USE MARKET FORECASTS AND ANALYSIS
8.3. ONCOLOGY
8.3.1. Overview
8.3.2. Oncology Market Forecast and Analysis
8.4. ORGAN TRANSPLANT
8.4.1. Overview
8.4.2. Organ transplant Market Forecast and Analysis
8.5. GASTROINTESTINAL
8.5.1. Overview
8.5.2. Gastrointestinal Market Forecast and Analysis
8.6. OTHERS
8.6.1. Overview
8.6.2. Others Market Forecast and Analysis
9. EVEROLIMUS MARKET - REVENUE AND FORECASTS TO 2028 - DISTRIBUTION CHANNEL
9.1. OVERVIEW
9.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
9.3. HOSPITALS
9.3.1. Overview
9.3.2. Hospitals Market Forecast and Analysis
9.4. PHARMACY
9.4.1. Overview
9.4.2. Pharmacy Market Forecast and Analysis
9.5. OTHERS
9.5.1. Overview
9.5.2. Others Market Forecast and Analysis
10. EVEROLIMUS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Everolimus Market Overview
10.1.2 North America Everolimus Market Forecasts and Analysis
10.1.3 North America Everolimus Market Forecasts and Analysis - By Type
10.1.4 North America Everolimus Market Forecasts and Analysis - By End Use
10.1.5 North America Everolimus Market Forecasts and Analysis - By Distribution Channel
10.1.6 North America Everolimus Market Forecasts and Analysis - By Countries
10.1.6.1 United States Everolimus Market
10.1.6.1.1 United States Everolimus Market by Type
10.1.6.1.2 United States Everolimus Market by End Use
10.1.6.1.3 United States Everolimus Market by Distribution Channel
10.1.6.2 Canada Everolimus Market
10.1.6.2.1 Canada Everolimus Market by Type
10.1.6.2.2 Canada Everolimus Market by End Use
10.1.6.2.3 Canada Everolimus Market by Distribution Channel
10.1.6.3 Mexico Everolimus Market
10.1.6.3.1 Mexico Everolimus Market by Type
10.1.6.3.2 Mexico Everolimus Market by End Use
10.1.6.3.3 Mexico Everolimus Market by Distribution Channel
10.2. EUROPE
10.2.1 Europe Everolimus Market Overview
10.2.2 Europe Everolimus Market Forecasts and Analysis
10.2.3 Europe Everolimus Market Forecasts and Analysis - By Type
10.2.4 Europe Everolimus Market Forecasts and Analysis - By End Use
10.2.5 Europe Everolimus Market Forecasts and Analysis - By Distribution Channel
10.2.6 Europe Everolimus Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Everolimus Market
10.2.6.1.1 Germany Everolimus Market by Type
10.2.6.1.2 Germany Everolimus Market by End Use
10.2.6.1.3 Germany Everolimus Market by Distribution Channel
10.2.6.2 France Everolimus Market
10.2.6.2.1 France Everolimus Market by Type
10.2.6.2.2 France Everolimus Market by End Use
10.2.6.2.3 France Everolimus Market by Distribution Channel
10.2.6.3 Italy Everolimus Market
10.2.6.3.1 Italy Everolimus Market by Type
10.2.6.3.2 Italy Everolimus Market by End Use
10.2.6.3.3 Italy Everolimus Market by Distribution Channel
10.2.6.4 Spain Everolimus Market
10.2.6.4.1 Spain Everolimus Market by Type
10.2.6.4.2 Spain Everolimus Market by End Use
10.2.6.4.3 Spain Everolimus Market by Distribution Channel
10.2.6.5 United Kingdom Everolimus Market
10.2.6.5.1 United Kingdom Everolimus Market by Type
10.2.6.5.2 United Kingdom Everolimus Market by End Use
10.2.6.5.3 United Kingdom Everolimus Market by Distribution Channel
10.2.6.6 Rest of Europe Everolimus Market
10.2.6.6.1 Rest of Europe Everolimus Market by Type
10.2.6.6.2 Rest of Europe Everolimus Market by End Use
10.2.6.6.3 Rest of Europe Everolimus Market by Distribution Channel
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Everolimus Market Overview
10.3.2 Asia-Pacific Everolimus Market Forecasts and Analysis
10.3.3 Asia-Pacific Everolimus Market Forecasts and Analysis - By Type
10.3.4 Asia-Pacific Everolimus Market Forecasts and Analysis - By End Use
10.3.5 Asia-Pacific Everolimus Market Forecasts and Analysis - By Distribution Channel
10.3.6 Asia-Pacific Everolimus Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Everolimus Market
10.3.6.1.1 Australia Everolimus Market by Type
10.3.6.1.2 Australia Everolimus Market by End Use
10.3.6.1.3 Australia Everolimus Market by Distribution Channel
10.3.6.2 China Everolimus Market
10.3.6.2.1 China Everolimus Market by Type
10.3.6.2.2 China Everolimus Market by End Use
10.3.6.2.3 China Everolimus Market by Distribution Channel
10.3.6.3 India Everolimus Market
10.3.6.3.1 India Everolimus Market by Type
10.3.6.3.2 India Everolimus Market by End Use
10.3.6.3.3 India Everolimus Market by Distribution Channel
10.3.6.4 Japan Everolimus Market
10.3.6.4.1 Japan Everolimus Market by Type
10.3.6.4.2 Japan Everolimus Market by End Use
10.3.6.4.3 Japan Everolimus Market by Distribution Channel
10.3.6.5 South Korea Everolimus Market
10.3.6.5.1 South Korea Everolimus Market by Type
10.3.6.5.2 South Korea Everolimus Market by End Use
10.3.6.5.3 South Korea Everolimus Market by Distribution Channel
10.3.6.6 Rest of Asia-Pacific Everolimus Market
10.3.6.6.1 Rest of Asia-Pacific Everolimus Market by Type
10.3.6.6.2 Rest of Asia-Pacific Everolimus Market by End Use
10.3.6.6.3 Rest of Asia-Pacific Everolimus Market by Distribution Channel
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Everolimus Market Overview
10.4.2 Middle East and Africa Everolimus Market Forecasts and Analysis
10.4.3 Middle East and Africa Everolimus Market Forecasts and Analysis - By Type
10.4.4 Middle East and Africa Everolimus Market Forecasts and Analysis - By End Use
10.4.5 Middle East and Africa Everolimus Market Forecasts and Analysis - By Distribution Channel
10.4.6 Middle East and Africa Everolimus Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Everolimus Market
10.4.6.1.1 South Africa Everolimus Market by Type
10.4.6.1.2 South Africa Everolimus Market by End Use
10.4.6.1.3 South Africa Everolimus Market by Distribution Channel
10.4.6.2 Saudi Arabia Everolimus Market
10.4.6.2.1 Saudi Arabia Everolimus Market by Type
10.4.6.2.2 Saudi Arabia Everolimus Market by End Use
10.4.6.2.3 Saudi Arabia Everolimus Market by Distribution Channel
10.4.6.3 U.A.E Everolimus Market
10.4.6.3.1 U.A.E Everolimus Market by Type
10.4.6.3.2 U.A.E Everolimus Market by End Use
10.4.6.3.3 U.A.E Everolimus Market by Distribution Channel
10.4.6.4 Rest of Middle East and Africa Everolimus Market
10.4.6.4.1 Rest of Middle East and Africa Everolimus Market by Type
10.4.6.4.2 Rest of Middle East and Africa Everolimus Market by End Use
10.4.6.4.3 Rest of Middle East and Africa Everolimus Market by Distribution Channel
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Everolimus Market Overview
10.5.2 South and Central America Everolimus Market Forecasts and Analysis
10.5.3 South and Central America Everolimus Market Forecasts and Analysis - By Type
10.5.4 South and Central America Everolimus Market Forecasts and Analysis - By End Use
10.5.5 South and Central America Everolimus Market Forecasts and Analysis - By Distribution Channel
10.5.6 South and Central America Everolimus Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Everolimus Market
10.5.6.1.1 Brazil Everolimus Market by Type
10.5.6.1.2 Brazil Everolimus Market by End Use
10.5.6.1.3 Brazil Everolimus Market by Distribution Channel
10.5.6.2 Argentina Everolimus Market
10.5.6.2.1 Argentina Everolimus Market by Type
10.5.6.2.2 Argentina Everolimus Market by End Use
10.5.6.2.3 Argentina Everolimus Market by Distribution Channel
10.5.6.3 Rest of South and Central America Everolimus Market
10.5.6.3.1 Rest of South and Central America Everolimus Market by Type
10.5.6.3.2 Rest of South and Central America Everolimus Market by End Use
10.5.6.3.3 Rest of South and Central America Everolimus Market by Distribution Channel
11. IMPACT OF COVID-19 PANDEMIC ON GLOBAL EVEROLIMUS MARKET
11.1 North America
11.2 Europe
11.3 Asia-Pacific
11.4 Middle East and Africa
11.5 South and Central America
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. EVEROLIMUS MARKET, KEY COMPANY PROFILES
13.1. NOVARTIS
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. BISCON
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. TRANSOPHARM
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. TECOLAND CORPORATION
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. GONANE PHARMA
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. BIOCON LIMITED
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. BRAWN LABORATORIES LTD.
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. BRIGHT GENE BIO-MEDICAL TECHNOLOGY
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. CIPLA
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. CONCORD BIOTECH
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
The List of Companies

1. Novartis
2. Biscon
3. Transopharm
4. Tecoland Corporation
5. Gonane Pharma
6. Biocon Limited
7. Brawn Laboratories Ltd.
8. Bright Gene Bio-Medical Technology
9. Cipla
10. Concord Biotech
11. Omgen Lifesciences
TIPRE00022705
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking